The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A first-in-human phase 1 study of anticancer stem cell agent OMP-54F28 (FZD8-Fc), decoy receptor for WNT ligands, in patients with advanced solid tumors.
Antonio Jimeno
Research Funding - OncoMed
Michael S. Gordon
No relevant relationships to disclose
Rashmi Chugh
No relevant relationships to disclose
Wells A. Messersmith
Consultant or Advisory Role - OncoMed (U)
Research Funding - OncoMed
David S. Mendelson
No relevant relationships to disclose
Jakob Dupont
Employment or Leadership Position - OncoMed
Stock Ownership - OncoMed
Robert J. Stagg
Employment or Leadership Position - OncoMed
Stock Ownership - OncoMed
Ann Kapoun
Employment or Leadership Position - OncoMed
Stock Ownership - OncoMed
Lu Xu
Employment or Leadership Position - OncoMed
Stock Ownership - OncoMed
Rainer Karl Brachmann
Employment or Leadership Position - OncoMed
Stock Ownership - OncoMed
David C. Smith
Research Funding - OncoMed